Clinical Trial Update: Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated the safety, pharmacokinetics, and efficacy of RA-18C3 in adults with moderate-to-severe psoriasis. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• RA-18C3

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Psoriasis | Phase 2 | Status: COMPLETED